Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, comments on the future of upfront treatments for T-cell lymphomas, in particular highlighting a study of Pi3 kinase in the upfront setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Deepa Jagadeesh, MD, PhD, has received research funding from ADC Therapeutics, AstraZeneca, Debiopharm Group, MEI Pharma, Regeneron, Rhizen Pharma, Seagen, Trillium Therapeutics and LOXO Pharma.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.